DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hrvznz/china_heparin) has announced the addition of the "China Heparin Industry Report, 2012-2014" report to their offering.
China has become one of the world's largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually. Due to the euro debt crisis, the global market suffered a deep recession. Coupled that the heparin export standard has lifted, China's export volume of heparin API was no more than 105.2 tons in 2011, approximating 14.6 trillion units (measured by 140IU/mg), with the proportion of around 45.9% in the global demand during the same period.
According to public information issued by related enterprises, the heparin API capacity of China will increase by more than 18 trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over 70% of the global demand.
Although China is a large country with rich heparin API, the downstream production of general heparin preparation and low molecular weight heparin preparation is still at the initial stage. In the high-end low molecular weight heparin preparation market, especially, joint ventures and foreign brands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. According to China Pharmaceutical Industry Association, imported low molecular weight heparin calcium accounted for more than 60% of the total procurement of such products of representative hospitals in 22 Chinese cities in 2011.
However, with the improvement of R&D and technological strength, the competitiveness of made-in-China low molecular weight heparin preparation market is increasingly enhancing.
Key Topics Covered:
1. Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain
2. Operating Environment of Chinese Heparin Industry
2.1 Entry Barriers
2.1.1 Policies
2.1.2 Technical Requirements
2.1.3 Capital Barrier
2.2 Supply and Demand in Global Market
2.3 Competition in Global Market
2.4 Global Market Forecast
3. Development of Heparin API Industry in China
3.1 Market Status Quo
3.2 Market Supply and Demand
3.3 Competitive Landscape
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Outlook & Forecast
4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Competition Pattern
4.3 Market Segments
4.3.1 Low Molecular Weight Heparin Preparation
4.3.2 General Heparin Preparation
4.4 Development Outlook & Forecast
5. Key Chinese Heparin Manufacturers
List of Charts
Companies Mentioned
- Changzhou Qianhong Bio-Pharma
- Hebei Changshan Biochemical Pharmaceutical
- Nanjing King-Friend Biochemical Pharmaceutical
- Shenzhen Hepalink Pharmaceutical
- Tianjin Chase Sun Pharmaceutical
- Wanbang Biopharmaceuticals
- Yantai Dongcheng Biochemicals
For more information visit http://www.researchandmarkets.com/research/hrvznz/china_heparinP